Capricor Therapeutics (CAPR) Current Deferred Revenue: 2014-2025
Historic Current Deferred Revenue for Capricor Therapeutics (CAPR) over the last 7 years, with Sep 2025 value amounting to $12.0 million.
- Capricor Therapeutics' Current Deferred Revenue fell 8.61% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year decrease of 8.61%. This contributed to the annual value of $12.0 million for FY2024, which is 50.56% down from last year.
- Per Capricor Therapeutics' latest filing, its Current Deferred Revenue stood at $12.0 million for Q3 2025, which was down 0.00% from $12.0 million recorded in Q2 2025.
- In the past 5 years, Capricor Therapeutics' Current Deferred Revenue ranged from a high of $31.0 million in Q1 2023 and a low of $9.7 million during Q1 2022.
- Its 3-year average for Current Deferred Revenue is $18.7 million, with a median of $15.4 million in 2024.
- As far as peak fluctuations go, Capricor Therapeutics' Current Deferred Revenue surged by 218.85% in 2023, and later plummeted by 50.56% in 2024.
- Capricor Therapeutics' Current Deferred Revenue (Quarterly) stood at $18.0 million in 2022, then spiked by 34.98% to $24.3 million in 2023, then tumbled by 50.56% to $12.0 million in 2024, then dropped by 8.61% to $12.0 million in 2025.
- Its Current Deferred Revenue was $12.0 million in Q3 2025, compared to $12.0 million in Q2 2025 and $12.0 million in Q1 2025.